Effect of Sickle Cell Trait on the Treatment Response of Individuals Infected with Human Immune-Deficiency Virus (HIV)

Nkiruka Nonyelum Odunukwe

Clinical Science Department, Nigerian Institute of Medical Research, Yaba Lagos, Nigeria.

Jane Ogoamaka Okwuzu *

Clinical Science Department, Nigerian Institute of Medical Research, Yaba Lagos, Nigeria.

Adesola Zaidat Musa

Clinical Science Department, Nigerian Institute of Medical Research, Yaba Lagos, Nigeria.

Patricia Chinwe Austin-Akaigwe

Clinical Science Department, Nigerian Institute of Medical Research, Yaba Lagos, Nigeria.

Ahmed Rufai Abubakar

Clinical Science Department, Nigerian Institute of Medical Research, Yaba Lagos, Nigeria.

Babatunde Lawal Salako

Clinical Science Department, Nigerian Institute of Medical Research, Yaba Lagos, Nigeria.

*Author to whom correspondence should be addressed.


Abstract

Background: Sickle cell disease is of public health importance and comes with systemic organ complications that can cause long-term disabilities and early death.

Aim: This study was to determine the effect of co-existence between sickle cell gene (HbS) and HIV infection in a Lagos population.

Methods: The study was conducted at the anti-retroviral (ARV) outpatient clinic of the Nigerian Institute of Medical Research (NIMR), Yaba, Lagos. It is a cross-sectional cohort study of 292 adult HIV- positive patients who were enrolled for treatment and support in the centre between the year 2004-2015. A review of case notes and database was done to extract haematologic, immunologic, virologic and clinical information of the patients. The enrolled participants were invited for additional clinical and socio-demographic information using a structured questionnaire. Blood samples were collected and reanalysed to confirm the haemoglobin genotype. Data analysis was performed using SPSS software.

Results: Out of 292 recruited patients, 274 participants had complete data of which 74.1%, 22.9% and 2.9% were HbAA, HbAS and HbAC respectively. Sickle cell trait (SCT) was found in 25.9% of the participants and there was no record of sickle cell disease (SCD). HbAA participants were found to have a higher viral load (87.5%) at baseline (P < 0.001). For HbAA and SCT groups, treatment response over the years was similar with lower figures seen in SCT.

Conclusion: It was concluded that lower HIV viraemia in SCT might mean a delay in HIV-1 disease progression and subsequently better quality of life for such patients.

Keywords: Sickle cell disease, human immune-deficiency virus, disease progression, sickle cell trait


How to Cite

Odunukwe, Nkiruka Nonyelum, Jane Ogoamaka Okwuzu, Adesola Zaidat Musa, Patricia Chinwe Austin-Akaigwe, Ahmed Rufai Abubakar, and Babatunde Lawal Salako. 2023. “Effect of Sickle Cell Trait on the Treatment Response of Individuals Infected With Human Immune-Deficiency Virus (HIV)”. Journal of Advances in Microbiology 23 (2):9-18. https://doi.org/10.9734/jamb/2023/v23i2705.

Downloads

Download data is not yet available.